17-316 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid TumorsStatus: open
INCB 01158-101 (CX-1158-101) - Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Treatment for Lung Cancer
This study is an open-label Phase 1 evaluation of CB-1158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors. IRB Number 17-316
SponsorsThis trial is sponsored by Incyte Corporation.
Interested in Clinical Trial?
Providers Associated With This Trial
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology